Corrigendum to ‘Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma’: [Annals of Oncology 34 (2023) 806-812]

C.E. Sharon, G.N. Tortorello, K.L. Ma, A.C. Huang, X. Xu, L.R. Giles, S. McGettigan, K. Kreider, L.M. Schuchter, A.J. Mathew, R.K. Amaravadi, P.A. Gimotty, J.T. Miura, G.C. Karakousis,T.C. Mitchell

Annals of Oncology（2024）

引用 0|浏览0